2.96 USD
+0.13 (+4.59%)
FWBI gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. Both the profitability and financial health of FWBI have multiple concerns. FWBI does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past year FWBI has reported negative net income.
- In the past year FWBI has reported a negative cash flow from operations.
- In the past 5 years FWBI always reported negative net income.
- FWBI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- FWBI's Return On Assets of -233.87% is on the low side compared to the rest of the industry. FWBI is outperformed by 92.62% of its industry peers.
- FWBI has a worse Return On Equity (-446.80%) than 78.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -233.87% | ||
| ROE | -446.8% | ||
| ROIC | N/A |
ROA(3y)-408.67%
ROA(5y)-343.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for FWBI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The number of shares outstanding for FWBI has been increased compared to 1 year ago.
- The debt/assets ratio for FWBI has been reduced compared to a year ago.
2.2 Solvency
- FWBI has an Altman-Z score of -43.89. This is a bad value and indicates that FWBI is not financially healthy and even has some risk of bankruptcy.
- FWBI's Altman-Z score of -43.89 is on the low side compared to the rest of the industry. FWBI is outperformed by 94.34% of its industry peers.
- FWBI has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
- FWBI's Debt to Equity ratio of 0.17 is on the low side compared to the rest of the industry. FWBI is outperformed by 66.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -43.89 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- FWBI has a Current Ratio of 1.58. This is a normal value and indicates that FWBI is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.58, FWBI is doing worse than 81.13% of the companies in the same industry.
- FWBI has a Quick Ratio of 1.58. This is a normal value and indicates that FWBI is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of FWBI (1.58) is worse than 79.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.58 | ||
| Quick Ratio | 1.58 |
3. Growth
3.1 Past
- FWBI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 75.50%, which is quite impressive.
EPS 1Y (TTM)75.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 14.93% on average over the next years. This is quite good.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y95.87%
EPS Next 2Y40.79%
EPS Next 3Y25.45%
EPS Next 5Y14.93%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- FWBI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year FWBI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as FWBI's earnings are expected to grow with 25.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.79%
EPS Next 3Y25.45%
5. Dividend
5.1 Amount
- No dividends for FWBI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FIRST WAVE BIOPHARMA / FWBI FAQ
What is the ChartMill fundamental rating of FIRST WAVE BIOPHARMA (FWBI) stock?
ChartMill assigns a fundamental rating of 1 / 10 to FWBI.
Can you provide the valuation status for FIRST WAVE BIOPHARMA?
ChartMill assigns a valuation rating of 1 / 10 to FIRST WAVE BIOPHARMA (FWBI). This can be considered as Overvalued.
What is the profitability of FWBI stock?
FIRST WAVE BIOPHARMA (FWBI) has a profitability rating of 0 / 10.
What is the expected EPS growth for FIRST WAVE BIOPHARMA (FWBI) stock?
The Earnings per Share (EPS) of FIRST WAVE BIOPHARMA (FWBI) is expected to grow by 95.87% in the next year.